Citius Pharma subsidiary amends $3.8M note, adds conversion at $0.90, subordinates to senior debt

Citius Pharmaceuticals, Inc.

Third Amendment to Promissory Note dated May 4, 2026, between Citius Oncology and Citius Pharmaceuticals.
Entire unpaid principal balance of $3.8M now due 91 days after senior debt fully paid and loan agreement terminated.
Prior maturity triggers from capital raises, debt/equity issuance, or royalty monetization eliminated.
New voluntary conversion feature allows parent to convert principal into shares at $0.90 per share, subject to subsidiary approval.
Note subordinated to Avenue Venture Opportunities Fund's senior debt; cash prepayment prohibited before new maturity.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Citius Pharmaceuticals, Inc. amended Third Amendment to Promissory Note with Citius Oncology, Inc. (effective 2026-05-04).

Action: amendment
Counterparty: Citius Oncology, Inc.
Effective: 2026-05-04

Exact text from the filing

the Company and Citius Oncology entered into a Third Amendment to Promissory Note (the “Third Amendment”), which amends the promissory note, dated August 16, 2024, as previously amended on September 10, 2025 and December 10, 2025, issued by the Citius Oncology to the Company in the original principal amount of $3,800,111 (the “Promissory Note”)

View on SEC.gov

Browse all material agreements →

Citius Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-053916

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.